cost-effectiveness research

Research in Review

Pazopanib Cost-Effective for Patients With Renal Cell Carcinoma

03/28/2017

JCP Editors

Medicare patients with advanced renal cell carcinoma benefit from lower costs and hospital admissions if treated with pazopanib rather than sunitinib, according to research presented at the AMCP Managed Care &...

...

03/28/2017

Journal of Clinical Pathways

Department

Cancer Survivors Largely Undereducated About Costs Prior to Treatment

03/15/2017

JCP Editors

Greater than one-half of cancer survivors reported experiencing some degree of financial distress following treatment, according to a study conducted by the LIVESTRONG Foundation (Austin, TX). ----- Related...

...

03/15/2017

Journal of Clinical Pathways

Research in Review

Lower Dosage of Prostate Cancer Drug Equally Effective When Taken With Low-Fat Meal

02/17/2017

JCP Editors

Taking one-fourth the recommended dose of a standard drug with a low-fat meal is as effective as taking the recommended dose on an empty stomach for patients with castration-resistant prostate cancer, according to...

Taking...

02/17/2017

Journal of Clinical Pathways

Research in Review

Cost-Effectiveness of Non–Guideline-Adherent Treatments Varies

02/13/2017

JCP Editors

Treatment preferences that do not adhere to clinical guidelines may still be cost-effective, according to a series of recently published case reports. Patients preferences for treatment sometimes divert from...

...

02/13/2017

Journal of Clinical Pathways

Research in Review

Most Cost-Effective Sequence of TKIs for Treatment of GISTs Identified

01/10/2017

JCP Editors

The best potential strategy involving tyrosine kinase inhibitors (TKIs) for the treatment of gastrointestinal stromal tumors (GISTs) has been identified, according to new research published in Clinical Drug...

The...

01/10/2017

Journal of Clinical Pathways

Research in Review

12/29/2016

JCP Editors

A new study sheds light on factors that make it more likely patients with cancer will not adhere to their treatment because of cost reasons. ----- Related Content Cognitive Factors Linked to Treatment Adherence in...

A new...

12/29/2016

Journal of Clinical Pathways

Research in Review

Hormone Receptor-Negative Breast Cancers Gain Greatest Economic Benefit from Trastuzumab

12/13/2016

JCP Editors

The cost-effectiveness of adjuvant trastuzumab (Herceptin, Genentech) may vary based on patient age and disease subtype among women with HER2-positive breast cancer, according to study results published in PLoS...

The...

12/13/2016

Journal of Clinical Pathways

Research in Review

Stepped Care Program Targeting Psychological Distress Deemed Cost-Effective

12/09/2016

JCP Editors

A stepped care program has been deemed more cost-effective than care-as-usual in patients with head and neck cancer or lung cancer who have psychological distress, according to a recent study published in the Journal...

A...

12/09/2016

Journal of Clinical Pathways

Research in Review

Trastuzumab Biosimilar Approval Could Improve Access to Treatment For Breast Cancer

12/05/2016

JCP Editors

The potential FDA approval of a new biosimilar to trastuzumab may help increase access to the treatment, which is recommended as first-line therapy for patients with ERBB2 (HER2)-positive breast...

The...

12/05/2016

Journal of Clinical Pathways

Research in Review

Pembrolizumab More Cost Effective Than Docetaxel for PD-L1-Positive NSCLC

10/31/2016

JCP Editors

The associated improvement in survival and quality-adjusted life years (QALYs) makes pembrolizumab a more cost-effective option than docetaxel for patients with programmed death ligand 1 (PD-L1)-positive non-small...

The...

10/31/2016

Journal of Clinical Pathways